Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Articles of Association of Genmab A/S21 Dec 2011
Genmab Announces Progress with DuoBody™ Platform20 Dec 2011
Genmab Announces Progress with Lundbeck Collaboration15 Dec 2011
Genmab Announces Preliminary Safety and Efficacy Data for Daratumumab11 Dec 2011
Genmab's Financial Calendar for 20128 Dec 2011
Grant of Warrants to Employees in Genmab8 Dec 2011
Genmab Announces Appeal of US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit6 Dec 2011
Genmab Announces US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
17 Nov 2011
Multiple Data for Ofatumumab and Daratumumab to be presented at ASH8 Nov 2011
Genmab Announces Financial Results for the First Nine Months of 2011 and Updated 2011 Financial Guidance2 Nov 2011
Articles of Association of Genmab A/S28 Oct 2011
Arzerra Third Quarter 2011 Net Sales Figures26 Oct 2011
  • Previous
  • 1
  • More pages
  • 94
  • 95
  • 96
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863